Jaguar health to participate in bio international convention (bio 2022)

Jaguar seeking partnering meetings at bio 2022 related to the company's novel plant-based fda-approved anti-secretory agent for cancer therapy-related diarrhea (ctd) and inflammatory bowel disease (ibd) and its large proprietary library of medicinal plants, including plants with novel psychedelic and other psychoactive effects san francisco, ca / accesswire / june 10, 2022 / jaguar health, inc. (nasdaq:jagx) today announced that karen brunke, phd, the company's executive vice president of corporate and business development, will be attending bio 2022, taking place at the san diego convention center from june 13 - 16, 2022. dr. brunke will be participating in one-on-one meetings throughout the conference.
JAGX Ratings Summary
JAGX Quant Ranking